Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 15, 2014

View Archived Issues

Phase II results for field-mixed avian influenza A/H7N9 vaccine with MF59 adjuvant

RAPID-PsA phase III results for certolizumab pegol in patients with active psoriasis

Stada Arzneimittel in-licenses teriparatide biosimilar

Identification of a novel druggable target for the development of new anxiolytics

Rigontec in first closing of Series A financing

Promising results presented for the novel EGFR tyrosine kinase inhibitor, AZD-9291

GAPVAC consortium advances a personalized cancer vaccine approach into the clinic for glioblastoma

In vitro inhibition of Middle East respiratory syndrome coronavirus with BanLec

Cutaneous tolerability and therapeutic benefits of LAS-41010

Phase I data for MPDL-3280A for the treatment of UBC and other malignancies

Researchers at Merck & Co. disclose new agents for Alzheimer's disease

A team of scientists at Amgen synthesizes novel protease inhibitors

Merck Sharp & Dohme designs new tyrosine-protein kinase inhibitors

Researchers at Roche present novel A-FABP inhibitors

Seragon Pharmaceuticals designs novel ER-alpha ligands for cancer and other disorders

GW Pharmaceuticals reports topline results from the phase IIa GWP-42003 trial

Aethlon Medical uses Hemopurifier blood filtration device in patient with Ebola virus infection

Raze Therapeutics formed to target mitochondrial one-carbon metabolism in cancer cells

Mochida and LG Life Sciences enter adalimumab biosimilar agreement

MRC Technology and Proximagen collaborate in inflammatory and autoimmune diseases

FDA grants olaratumab orphan drug status for soft tissue sarcoma

Resimmune receives orphan designation for cutaneous T-cell lymphoma in the U.S.

FDA grants priority review to rufinamide sNDA

FDA approves Quidel's Lyra Adenovirus Assay

Sorrento Therapeutics plans to reduce sample size in Cynviloq bioequivalence study

Zenith Epigenetics suspends development of ZEN-3365

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...